6-azido-2,4(1H,3H)pyrimidinedione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-azido-2,4(1H,3H)pyrimidinedione
• 英文别名: 6-Azidouracil；6-azido-1H-pyrimidine-2,4-dione
• 化学式: C₄H₃N₅O₂
• 分子量: 153.1
• InChiKey: IMNCTGDMBREYLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  烯丙基三苯基溴化膦 、 6-azido-2,4(1H,3H)pyrimidinedione 在 lithium hydride 作用下， 以 丁酮 为溶剂， 反应 2.0h， 以36%的产率得到1H-吡咯并[3,2-d]嘧啶-2,4(3H,5H)-二酮
  参考文献：
  名称：

  由 6-叠氮脲嘧啶和叶立德正膦轻松合成吡咯并[3,2-d]嘧啶

  摘要：

  AbstractA series of the title compounds, 9‐deazaxanthines, was regioselectively prepared in reasonable yields as major products from the reactions of 6‐azidouracils 1a,b with stabilized ester‐2a,b or keto‐2c ylide phosphoranes and a moderated phosphorus ylide 3, instead of the expected triazoles. Side products were also observed wherein pyrimido[5,4‐g]pteridine‐2,4,5,7‐tetrone (15) and other fused ring systems or acyclic‐substituted uracil derivatives were isolated. A comparative study on the reactivity of 1a in analogy to 1b toward phosphoranes is also described. © 2002 Wiley Periodicals, Inc. Heteroatom Chem 13:357–365, 2002; Published online in Wiley Interscience (www.interscience.wiley.com). DOI 10.1002/hc.10048

  DOI：

  10.1002/hc.10048
• 作为产物：
  描述：

  chlorouracil E 、 叠氮化钠 以to give 6-azidouracil 20的产率得到6-azido-2,4(1H,3H)pyrimidinedione
  参考文献：
  名称：

  Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors

  摘要：

  本发明提供了由式子IZ—L—R1—Q—D—（V1）m—R2或其药学上可接受的盐所定义的化合物，其中Z，L，R1，Q，D，V1，m和R2在规范中有定义。本发明还提供了制药组合物，包括由规范中定义的式子I或其药学上可接受的盐所定义的化合物，以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了抑制动物中MMP-13酶的方法，包括向动物投与式子I或其药学上可接受的盐所定义的化合物。本发明还提供了治疗患有由MMP-13酶介导的疾病的患者的方法，包括向患者投与式子I或其药学上可接受的盐所定义的化合物，单独使用或在制药组合物中使用。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、非骨关节炎或类风湿性关节炎的关节炎、心力衰竭、炎症性肠病、老年性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周疾病、银屑病、动脉硬化和骨质疏松症的患者的方法，包括向患者投与式子I或其药学上可接受的盐所定义的化合物，单独使用或在制药组合物中使用。本发明还提供了由式子I或其药学上可接受的盐所定义的化合物与规范中描述的另一种药物活性成分的组合。

  公开号：

  US20040063673A1

文献信息

• Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040063673A1

  公开（公告）日：2004-04-01

  This invention provides compounds defined by Formula I Z—L—R 1 —Q—D—(V 1 ) m —R 2 I or a pharmaceutically acceptable salt thereof, wherein Z, L, R 1 , Q, D, V 1 , m, and R 2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由式子IZ—L—R1—Q—D—（V1）m—R2或其药学上可接受的盐所定义的化合物，其中Z，L，R1，Q，D，V1，m和R2在规范中有定义。本发明还提供了制药组合物，包括由规范中定义的式子I或其药学上可接受的盐所定义的化合物，以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了抑制动物中MMP-13酶的方法，包括向动物投与式子I或其药学上可接受的盐所定义的化合物。本发明还提供了治疗患有由MMP-13酶介导的疾病的患者的方法，包括向患者投与式子I或其药学上可接受的盐所定义的化合物，单独使用或在制药组合物中使用。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、非骨关节炎或类风湿性关节炎的关节炎、心力衰竭、炎症性肠病、老年性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周疾病、银屑病、动脉硬化和骨质疏松症的患者的方法，包括向患者投与式子I或其药学上可接受的盐所定义的化合物，单独使用或在制药组合物中使用。本发明还提供了由式子I或其药学上可接受的盐所定义的化合物与规范中描述的另一种药物活性成分的组合。
• A facile synthesis of pyrrolo[3,2-d]pyrimidines from 6-azidouracils and ylide phosphoranes
  作者：Wafaa M. Abdou、Amin F. M. Fahmy、Azza A. Kamel

  DOI：10.1002/hc.10048

  日期：——

  AbstractA series of the title compounds, 9‐deazaxanthines, was regioselectively prepared in reasonable yields as major products from the reactions of 6‐azidouracils 1a,b with stabilized ester‐2a,b or keto‐2c ylide phosphoranes and a moderated phosphorus ylide 3, instead of the expected triazoles. Side products were also observed wherein pyrimido[5,4‐g]pteridine‐2,4,5,7‐tetrone (15) and other fused ring systems or acyclic‐substituted uracil derivatives were isolated. A comparative study on the reactivity of 1a in analogy to 1b toward phosphoranes is also described. © 2002 Wiley Periodicals, Inc. Heteroatom Chem 13:357–365, 2002; Published online in Wiley Interscience (www.interscience.wiley.com). DOI 10.1002/hc.10048
• 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040224951A1

  公开（公告）日：2004-11-11

  This invention provides compounds defined by Formula I 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, Y 5 , Y 6 , Y 8 , R 2 , R 4 , and R 7 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由公式I1定义的化合物或其药学上可接受的盐，其中R1、Q、Y5、Y6、Y8、R2、R4和R7如规范中所定义。本发明还提供了包括公式I中定义的化合物或其药学上可接受的盐的制药组合物，以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了在动物体内抑制MMP-13酶的方法，包括向动物体内给予公式I中定义的化合物或其药学上可接受的盐。本发明还提供了治疗由MMP-13酶介导的疾病的方法，包括向患者体内给予公式I中定义的化合物或其药学上可接受的盐，单独或与制药组合物一起。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎、除骨关节炎或类风湿性关节炎外的其他关节炎、心力衰竭、炎症性肠病、心力衰竭、年龄相关性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周疾病、银屑病、动脉粥样硬化和骨质疏松症的方法，包括向患者体内给予公式I中定义的化合物或其药学上可接受的盐，单独或与制药组合物一起。本发明还提供了包括公式I中定义的化合物或其药学上可接受的盐和规范中描述的另一种药学活性成分的组合物。